Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Stryker Corporation (SYK) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Stryker CorporationTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Stryker Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Stryker Corporation trades at $344.98 (market cap $133.54B), while Vertex Pharmaceuticals Incorporated trades at $529.34 (market cap $134.25B). The key difference: Stryker Corporation and Vertex Pharmaceuticals Incorporated are close in size by market cap, and Stryker Corporation pays a 1.01% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.

SYKVRTX
Market Cap
$133.54B$134.25B
Sector
TechnologyHealth
52-Week High
$394.34$529.65
52-Week Low
$282.58$376.62
Enterprise Value
$145.01B$128.37B
Dividend Yield
1.01%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Stryker Corporation

Stryker (SYK) trades at $341.17, down 1.34% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $379.44. The company reported strong Q2 2026 results with a 9% organic sales growth and an EPS beat, recovering from a Q1 cyber incident. Profitability remains robust with a net income margin of 14.43% and a dividend yield supported by recent increases.

The stock offers upside potential driven by earnings momentum and product innovation like Mako RPS, but risks include competitive pressures and past cybersecurity disruptions. Analyst sentiment is strongly bullish with 74% buy ratings, though valuation multiples like a P/E of 36.08 suggest premium pricing relative to historical norms.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.

Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX